Dr. Steve Stone on the Active Surveillance Threshold

Active surveillance is an increasingly popular treatment option for men diagnosed with prostate cancer. However, in order to select men for this cancer treatment option, better risk stratification is needed. Fortunately, in this video, you will see how the cell cycle progression (CCP) score has become a strong factor in predicting prostate cancer outcomes in various clinical settings.

Of the 505 men that were tested in Myriad Genetics clinical laboratory, and based on their clinical characteristics only, twenty-nine percent of patients would qualify for active surveillance. In contrast, 55% of patients fell below the active surveillance threshold when Prolaris was included in determining risk.

Why choose Active Surveillance for your patients?

The choice of active surveillance is suitable for patients with low-risk prostate cancer. As a result, the Prostate Cancer Foundation found that men with low-risk prostate cancer 10-15 years after their diagnosis who go on active surveillance, have much lower rates of the cancer spreading or dying from the disease.

For a patient with low-risk prostate cancer, you may decide that this is the best treatment option for them. According to the American Cancer Society, this approach may be beneficial if your patient’s cancer:

  • Isn’t causing any symptoms
  • Is expected to grow slowly (Based on their Gleason score and Prolaris score)
  • The tumor is small
  • The cancer is just in the prostate

 

In Conclusion:

For patients considering different treatment options, Prolaris provides important prognostic information at disease diagnosis. In addition, the Prolaris threshold provided in this video is considered to be “typical” for patients considering active surveillance in the U.S. Lastly, it can also be used to determine which of your patients would be good candidates for active surveillance, based on risk assessment.

Interested in ordering Prolaris for your patients? Get started with our Prolaris ordering process today.